NM_030662.4:c.303+1965C>T

Variant summary

Our verdict is Benign. The variant received -12 ACMG points: 0P and 12B. BP4_StrongBA1

The NM_030662.4(MAP2K2):​c.303+1965C>T variant causes a intron change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.0558 in 152,258 control chromosomes in the GnomAD database, including 256 homozygotes. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.

Frequency

Genomes: 𝑓 0.056 ( 256 hom., cov: 32)

Consequence

MAP2K2
NM_030662.4 intron

Scores

2

Clinical Significance

Not reported in ClinVar

Conservation

PhyloP100: -0.900

Publications

3 publications found
Variant links:
Genes affected
MAP2K2 (HGNC:6842): (mitogen-activated protein kinase kinase 2) The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]
MAP2K2 Gene-Disease associations (from GenCC):
  • cardiofaciocutaneous syndrome
    Inheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
  • cardiofaciocutaneous syndrome 4
    Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, PanelApp Australia, Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
  • neurofibromatosis-Noonan syndrome
    Inheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
  • Noonan syndrome
    Inheritance: AD Classification: LIMITED Submitted by: ClinGen

Genome browser will be placed here

ACMG classification

Classification was made for transcript

Our verdict: Benign. The variant received -12 ACMG points.

BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
BA1
GnomAd4 highest subpopulation (SAS) allele frequency at 95% confidence interval = 0.0635 is higher than 0.05.

Transcripts

RefSeq

Gene Transcript HGVSc HGVSp Effect Exon rank MANE Protein UniProt
MAP2K2NM_030662.4 linkc.303+1965C>T intron_variant Intron 2 of 10 ENST00000262948.10 NP_109587.1 P36507
MAP2K2NM_001440688.1 linkc.303+1965C>T intron_variant Intron 2 of 8 NP_001427617.1

Ensembl

Gene Transcript HGVSc HGVSp Effect Exon rank TSL MANE Protein Appris UniProt
MAP2K2ENST00000262948.10 linkc.303+1965C>T intron_variant Intron 2 of 10 1 NM_030662.4 ENSP00000262948.4 P36507
MAP2K2ENST00000394867.9 linkn.742+1965C>T intron_variant Intron 1 of 9 5
MAP2K2ENST00000599345.1 linkn.500+1965C>T intron_variant Intron 2 of 6 5
MAP2K2ENST00000687128.1 linkn.742+1965C>T intron_variant Intron 1 of 6

Frequencies

GnomAD3 genomes
AF:
0.0558
AC:
8495
AN:
152140
Hom.:
256
Cov.:
32
show subpopulations
Gnomad AFR
AF:
0.0491
Gnomad AMI
AF:
0.0143
Gnomad AMR
AF:
0.0374
Gnomad ASJ
AF:
0.0493
Gnomad EAS
AF:
0.0190
Gnomad SAS
AF:
0.0692
Gnomad FIN
AF:
0.0710
Gnomad MID
AF:
0.0633
Gnomad NFE
AF:
0.0645
Gnomad OTH
AF:
0.0541
We have no GnomAD4 exomes data on this position. Probably position not covered by the project.
GnomAD4 genome
AF:
0.0558
AC:
8498
AN:
152258
Hom.:
256
Cov.:
32
AF XY:
0.0547
AC XY:
4076
AN XY:
74454
show subpopulations
African (AFR)
AF:
0.0490
AC:
2036
AN:
41552
American (AMR)
AF:
0.0373
AC:
570
AN:
15290
Ashkenazi Jewish (ASJ)
AF:
0.0493
AC:
171
AN:
3472
East Asian (EAS)
AF:
0.0191
AC:
99
AN:
5186
South Asian (SAS)
AF:
0.0697
AC:
336
AN:
4824
European-Finnish (FIN)
AF:
0.0710
AC:
753
AN:
10602
Middle Eastern (MID)
AF:
0.0680
AC:
20
AN:
294
European-Non Finnish (NFE)
AF:
0.0645
AC:
4387
AN:
68016
Other (OTH)
AF:
0.0535
AC:
113
AN:
2112
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.500
Heterozygous variant carriers
0
404
809
1213
1618
2022
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance

Age Distribution

Genome Het
Genome Hom
Variant carriers
0
104
208
312
416
520
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
0.0609
Hom.:
125
Bravo
AF:
0.0523
Asia WGS
AF:
0.0380
AC:
134
AN:
3478

ClinVar

Not reported in ClinVar

Computational scores

Source: dbNSFP v4.3

Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
-0.86
CADD
Benign
0.072
DANN
Benign
0.43
PhyloP100
-0.90
Mutation Taster
=100/0
polymorphism (auto)

Splicing

Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
0.0
Details are displayed if max score is > 0.2

Find out detailed SpliceAI scores and Pangolin per-transcript scores at spliceailookup.broadinstitute.org

Publications

Other links and lift over

dbSNP: rs8101696; hg19: chr19-4115452; API